ArticleClinical cardiology2026
Serum Albumin Modifies the Prognostic Meaning of BNP in Acute Decompensated Heart Failure.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBNP is widely used for risk stratification in acute decompensated heart failure (ADHF), but its prognostic meaning may differ across clinical phenotypes, particularly cardiorenal syndrome type 1 (CRS1). HYPOTHESIS: We hypothesized that serum albumin modifies the association between BNP and adverse in-hospital course in ADHF.
methodsIn this retrospective cohort study, adults hospitalized with ADHF were classified as CRS1 or control. The primary endpoint was adverse in-hospital course, defined as in-hospital death and/or prolonged length of stay (≥ 75th percentile). BNP was analyzed on the natural log scale. Multivariable logistic regression included albumin, ln(BNP), and an albumin × ln(BNP) interaction term, adjusted for age, sex, systolic blood pressure, eGFR, ejection fraction, CRS status, body mass index, and diabetes mellitus.
resultsIn the complete-case cohort (N = 292; events = 77), albumin significantly modified the BNP-risk association (interaction β = -0.236 per 5 g/L; Wald p = 0.045; likelihood-ratio test p = 0.050). The adjusted odds ratio for a 1-unit increase in ln(BNP) was 1.81 at albumin 30 g/L, 1.42 at 35 g/L, and 1.12 at 40 g/L. Discrimination improved modestly with the interaction (AUC 0.714 vs. 0.726), and the high-BNP/low-albumin stratum showed the highest observed event risk.
conclusionsSerum albumin modifies the prognostic meaning of BNP in ADHF. Integrating albumin into BNP interpretation identifies a high-risk "congestion plus vulnerability" phenotype and may support pragmatic triage and discharge planning in CRS-enriched ADHF populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.